/TENX
TENX Stock - Tenax Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$13.10+2.18%
+$0.28 (+2.18%) • Dec 19
82
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.58
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+90.8%upside
Target: $24.99
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TENX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$12.97 – $13.23
TARGET (TP)$25.00
STOP LOSS$12.05
RISK/REWARD1:11.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.55
52W High$14.22
52W Low$4.63
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | $-114,748 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-19,494,000 | $-8,234,000 | $-11,052,643 | $-32,728,241 | $-9,867,930 |
| Net Income | $-17,602,000 | $-7,711,000 | $-11,047,895 | $-32,474,358 | $-9,851,391 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.15 | $-31.09 | $-600.80 | $-2524.80 | $-2125.38 |
Company Overview
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
3 Bullish0 Neutral/Bearish
Price Targets
$17
Average Target
↑ 32.3% Upside
Now
$16
Low
$17
Average
$20
High
Based on 3 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 8th 2025 | Piper Sandler | Initiation | Overweight | $20 |
| October 24th 2024 | Leerink Partners | Initiation | Outperform | $16 |
| October 14th 2024 | Guggenheim | Initiation | Buy | $16 |
| September 30th 2024 | William Blair | Initiation | Outperform | - |
Earnings History & Surprises
TENXBeat Rate
47%
Last 19 quarters
Avg Surprise
-6864.4%
EPS vs Estimate
Beats / Misses
9/9
1 met exactly
Latest EPS
$-0.40
Q4 2025
EPS Surprise History
Q1 24
-59.5%
$-12.98vs$-8.14
Q2 24
-30.0%
$-3.12vs$-2.40
Q3 24
+8.0%
$-1.83vs$-1.99
Q4 24
+86.2%
$-0.19vs$-1.38
Q1 25
+65.4%
$-0.18vs$-0.52
Q2 25
+41.7%
$-0.28vs$-0.48
Q3 25
+46.0%
$-0.27vs$-0.50
Q4 25
+69.9%
$-0.40vs$-1.33
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 24, 2026 | $-1.26 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-1.33 | $-0.40 | +69.9% | ✓ BEAT |
Q3 2025 | Aug 13, 2025 | $-0.50 | $-0.27 | +46.0% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $-0.48 | $-0.28 | +41.7% | ✓ BEAT |
Q1 2025 | Mar 25, 2025 | $-0.52 | $-0.18 | +65.4% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-1.38 | $-0.19 | +86.2% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-1.99 | $-1.83 | +8.0% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-2.40 | $-3.12 | -30.0% | ✗ MISS |
Q1 2024 | Mar 28, 2024 | $-8.14 | $-12.98 | -59.5% | ✗ MISS |
Q4 2023 | Nov 13, 2023 | $-7.20 | $-6.40 | +11.1% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-0.10 | $-4.00 | -3900.0% | ✗ MISS |
Q2 2023 | May 15, 2023 | $-0.37 | $-12.00 | -3143.2% | ✗ MISS |
Q1 2023 | Mar 30, 2023 | $-2.28 | $-1.73 | +24.1% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-176.00 | $-176.00 | 0.0% | = MET |
Q3 2022 | Aug 11, 2022 | $-144.00 | $-176.00 | -22.2% | ✗ MISS |
Q2 2022 | May 16, 2022 | $-144.00 | $-176.00 | -22.2% | ✗ MISS |
Q1 2022 | Mar 31, 2022 | $-3.20 | $-0.80 | +75.0% | ✓ BEAT |
Q4 2021 | Nov 16, 2021 | $-208.00 | $-240.00 | -15.4% | ✗ MISS |
Q3 2021 | Aug 16, 2021 | $-0.13 | $-160.00 | -122976.9% | ✗ MISS |
Q2 2021 | May 17, 2021 | $-336.00 | $-2624.00 | -681.0% | ✗ MISS |
Latest News
Tenax Therapeutics Announces Prespecified Blinded Sample Size Re-Estimation Of LEVEL Demonstrated Trial Is Powered At Well Over 90% To Detect 25 Meter Change In 6MWD, Primary Endpoint
📈 PositiveBenzinga•Dec 17, 2025, 02:20 PM
Guggenheim Maintains Buy on Tenax Therapeutics, Raises Price Target to $25
📈 PositiveBenzinga•Dec 17, 2025, 12:57 PM
Tenax Therapeutics Q3 EPS $(0.40) Misses $(0.32) Estimate
📉 NegativeBenzinga•Nov 12, 2025, 09:41 PM
Tenax Therapeutics To Host Webcast Highlighting TNX-103 Phase 3 Program For Pulmonary Hypertension In Heart Failure With Preserved Ejection Fraction
📈 PositiveBenzinga•Nov 6, 2025, 12:13 PM
Tenax Therapeutics Secures European Patent Protection For Levosimendan In PH-HFpEF Through 2040, Supporting Phase 3 LEVEL-2 Trial And Global IP Expansion
📈 PositiveBenzinga•Sep 16, 2025, 11:11 AM
Tenax Therapeutics Expands Global Rights to Develop and Manufacture Oral Levosimendan Under Amended Agreement with Orion
📈 PositiveBenzinga•Sep 9, 2025, 12:10 PM
Piper Sandler Initiates Coverage On Tenax Therapeutics with Overweight Rating, Announces Price Target of $20
📈 PositiveBenzinga•Sep 8, 2025, 10:39 AM
Frequently Asked Questions about TENX
What is TENX's current stock price?
Tenax Therapeutics, Inc. (TENX) is currently trading at $13.10 per share. The stock has moved +2.18% today.
What is the analyst price target for TENX?
The average analyst price target for TENX is $25.00, based on 1 analyst.
What sector is Tenax Therapeutics, Inc. in?
Tenax Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is TENX's market cap?
Tenax Therapeutics, Inc. has a market capitalization of $0.06 billion, making it a small-cap company.
Does TENX pay dividends?
No, Tenax Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANTX
AN2 Therapeutics, Inc.
$1.12
Mkt Cap: $0.0B
BOLD
Boundless Bio, Inc.
$1.22
Mkt Cap: $0.0B
JSPR
Jasper Therapeutics, Inc.
$1.86
Mkt Cap: $0.0B
NERV
Minerva Neurosciences, Inc.
$4.04
Mkt Cap: $0.0B
NXTC
NextCure, Inc.
$11.38
Mkt Cap: $0.0B
PLUR
Pluri Inc.
$3.40
Mkt Cap: $0.0B
PSTV
Plus Therapeutics, Inc.
$0.57
Mkt Cap: $0.0B
QTTB
Q32 Bio Inc.
$2.96
Mkt Cap: $0.0B
SABS
SAB Biotherapeutics, Inc.
$3.99
Mkt Cap: $0.0B
VRCA
Verrica Pharmaceuticals Inc.
$7.82
Mkt Cap: $0.1B
Explore stocks similar to TENX for comparison